Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, Laura Maria Fogliatto, Iara Gonçalves, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Michael Dickinson, Mieczysław Komarnicki, Andrew McDonald, Muhıt Özcan, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani